Publications by authors named "Samar Musa"
Background: Human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) are genetically related viruses and major causes of medically attended acute respiratory illness in children. Research comparing the severity of illnesses resulting from these infections lacks consensus.
Methods: Children younger than 18 years with acute respiratory illness were enrolled through active, prospective surveillance from 2016 to 2020 at 7 US pediatric hospitals and emergency departments (EDs).
Article Synopsis
- Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants in the U.S., prompting the CDC to recommend nirsevimab, a monoclonal antibody, for infants under 8 months and at-risk children aged 8-19 months to prevent severe infection during their first RSV season.
- In clinical trials, nirsevimab showed an 81% efficacy rate for preventing RSV-related hospitalizations, while a recent analysis during RSV season (October 2023-February 2024) reported a 90% effectiveness among treated infants.
- Despite limited numbers of treated infants, the findings support ongoing recommendations for nirsevimab and emphasize the importance of maternal vaccination or direct nirsevimab administration
Objective: To characterize the incidence of adverse events (AEs) associated with antibiotics used to treat acute otitis media in children.
Study Design: We searched MEDLINE for studies conducted between January 1, 1966, and August 25, 2018. Two authors independently assessed potential studies and extracted the data.